Publikation:

Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome

Lade...
Vorschaubild

Dateien

delRioOliva_2-1gh11i7lxub5p4.pdf
delRioOliva_2-1gh11i7lxub5p4.pdfGröße: 10.01 MBDownloads: 155

Datum

2022

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Hybrid
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

European Journal of Immunology. Wiley. 2022, 52(9), pp. 1510-1522. ISSN 0014-2980. eISSN 1521-4141. Available under: doi: 10.1002/eji.202249851

Zusammenfassung

Polymyositis (PM) is a chronic autoimmune inflammatory myopathy resulting in muscle weakness. The limited approved therapies and their poor efficacy contribute to its comorbidity. We investigated the therapeutic use of ONX 0914 and KZR-616, selective inhibitors of the immunoproteasome, in C protein-induced myositis (CIM), a mouse model of PM that closely resembles the human disease. Diseased mice (day 13 post-immunization) were treated with 10 mg/kg ONX 0914 or KZR-616 or vehicle on alternate days until day 28. Endpoints included muscle strength assessed by a grip strength meter, serum creatine kinase activity, histology, and immunohistochemistry analysis. Treatment with ONX 0914 or KZR-616 prevented the loss of grip strength in mice after CIM induction, while vehicle-treated animals displayed progressive muscle weakness. Immunoproteasome inhibition lowered PM-associated leukocyte infiltration of the muscle and prevented increased serum creatine kinase levels. LMP7-deficient mice were resistant to CIM induction as they depicted no alteration in the grip strength, creatine kinase (CK) levels, nor showed muscular alterations. In conclusion, selective inhibition of the immunoproteasome displays therapeutic efficacy in a pre-clinical mouse model of PM with suppression of muscle inflammation and preservation of muscle strength. Positive results from this study support the rationale for using KZR-616 in clinical studies.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690DEL RIO OLIVA, Marta, Christopher J. KIRK, Marcus GRÖTTRUP, Michael BASLER, 2022. Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome. In: European Journal of Immunology. Wiley. 2022, 52(9), pp. 1510-1522. ISSN 0014-2980. eISSN 1521-4141. Available under: doi: 10.1002/eji.202249851
BibTex
@article{DelRioOliva2022-09Effec-57851,
  year={2022},
  doi={10.1002/eji.202249851},
  title={Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome},
  number={9},
  volume={52},
  issn={0014-2980},
  journal={European Journal of Immunology},
  pages={1510--1522},
  author={Del Rio Oliva, Marta and Kirk, Christopher J. and Gröttrup, Marcus and Basler, Michael},
  note={This study was supported by the German Research Foundation (DFG) grant and SFB969 project C01 (to M.G.)}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/57851">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-06-28T05:48:21Z</dc:date>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57851/1/delRioOliva_2-1gh11i7lxub5p4.pdf"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:abstract xml:lang="eng">Polymyositis (PM) is a chronic autoimmune inflammatory myopathy resulting in muscle weakness. The limited approved therapies and their poor efficacy contribute to its comorbidity. We investigated the therapeutic use of ONX 0914 and KZR-616, selective inhibitors of the immunoproteasome, in C protein-induced myositis (CIM), a mouse model of PM that closely resembles the human disease. Diseased mice (day 13 post-immunization) were treated with 10 mg/kg ONX 0914 or KZR-616 or vehicle on alternate days until day 28. Endpoints included muscle strength assessed by a grip strength meter, serum creatine kinase activity, histology, and immunohistochemistry analysis. Treatment with ONX 0914 or KZR-616 prevented the loss of grip strength in mice after CIM induction, while vehicle-treated animals displayed progressive muscle weakness. Immunoproteasome inhibition lowered PM-associated leukocyte infiltration of the muscle and prevented increased serum creatine kinase levels. LMP7-deficient mice were resistant to CIM induction as they depicted no alteration in the grip strength, creatine kinase (CK) levels, nor showed muscular alterations. In conclusion, selective inhibition of the immunoproteasome displays therapeutic efficacy in a pre-clinical mouse model of PM with suppression of muscle inflammation and preservation of muscle strength. Positive results from this study support the rationale for using KZR-616 in clinical studies.</dcterms:abstract>
    <dcterms:issued>2022-09</dcterms:issued>
    <dc:contributor>Del Rio Oliva, Marta</dc:contributor>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-06-28T05:48:21Z</dcterms:available>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/57851/1/delRioOliva_2-1gh11i7lxub5p4.pdf"/>
    <dcterms:title>Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome</dcterms:title>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/57851"/>
    <dc:contributor>Basler, Michael</dc:contributor>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dc:language>eng</dc:language>
    <dc:creator>Basler, Michael</dc:creator>
    <dc:creator>Del Rio Oliva, Marta</dc:creator>
    <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
    <dc:creator>Kirk, Christopher J.</dc:creator>
    <dc:contributor>Kirk, Christopher J.</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

This study was supported by the German Research Foundation (DFG) grant and SFB969 project C01 (to M.G.)
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen